There is welcome news in the fight against Alzheimer’s disease, with an experimental Australian-developed medication showing promising signs of slowing the devastating condition in older patients.
The drug, known as Xanamem, has achieved encouraging results in a clinical trial involving 247 people in Australia and the United States, offering fresh hope that researchers may be moving closer to another treatment for the disease.
Developed by Australian biotechnology company Actinogen Medical, Xanamem was found to slow disease progression by 30 per cent in participants aged over 75, compared with those receiving a placebo.
For families watching a loved one gradually lose their memory, independence and ability to manage everyday life, even a modest slowing of the disease could make an enormous difference.
And researchers believe the latest findings provide an important reason to continue investigating the treatment.
A different approach to Alzheimer’s
Unlike some newer Alzheimer’s treatments that target the build-up of harmful proteins in the brain, Xanamem takes a different approach.
The medication, also known as emestedastat, works by blocking the production of excess cortisol, commonly known as the stress hormone, in important areas of the brain.
While cortisol plays an essential role in normal bodily functions, researchers believe excessive levels in the brain may contribute to the deterioration associated with Alzheimer’s disease.
By reducing cortisol production in these areas, scientists hope to protect brain function and slow the progression of symptoms.
Another encouraging feature is that Xanamem is taken as a daily tablet, potentially offering a simpler alternative to treatments that require regular infusions or injections.
During the 36-week trial, participants with mild to moderate Alzheimer’s disease received either the medication or a placebo.
The strongest results emerged among participants older than the trial’s median age of 75, who experienced approximately 30 per cent less disease progression than the comparison group.
Importantly, most participants experienced few side effects during the study.
However, researchers have stressed that the findings are preliminary. The drug did not demonstrate a statistically significant benefit across the entire trial population, meaning larger studies will be needed to establish whether the encouraging results in older patients can be repeated.
The next big step
Actinogen is already looking towards the next stage of development, with plans for a larger clinical trial involving approximately 700 patients.
That study is expected to begin in mid-2027 and will investigate whether Xanamem can consistently slow Alzheimer’s progression in a broader group of patients.
If successful, the company hopes the medication could become available around 2030, although that timeline depends on further trial results and approval from Australia’s Therapeutic Goods Administration.
Actinogen chief executive Dr Steven Gourlay said Australian research was playing an important role in answering some of medicine’s most challenging questions.
The company recently received a $10.8 million federal research and development tax incentive rebate, which Dr Gourlay said would help support its ongoing work.
“It encourages companies like us to do as much research in Australia as we can,” he said.
“So it’s been good for Australian jobs, it’s been good for Australian science, and it’s been great for helping companies like us to do the work that we need to do to answer important questions like, ‘Does this drug that controls cortisol work in Alzheimer’s disease?'”
Dr Gourlay also expressed hope that, should the drug ultimately prove successful and receive regulatory approval, it could eventually be made available through the Pharmaceutical Benefits Scheme.
That would be an important consideration for families facing the significant financial and emotional costs of Alzheimer’s care.
Hope for Australian families
The announcement comes at a critical time for dementia care in Australia.
According to Dementia Australia, approximately 446,500 Australians are currently living with dementia, with that number expected to exceed one million by 2065.
Alzheimer’s disease is the most common form of dementia, affecting memory, thinking, behaviour and, eventually, the ability to perform everyday tasks.
On the same day the Xanamem results were announced, Dementia Australia renewed its call for greater national investment in dementia prevention, diagnosis, treatment and support services.
Chief executive Professor Tanya Buchanan said urgent action was needed to improve outcomes for people living with dementia and those who care for them.
“The National Dementia Action Plan provides an important foundation, but sustained action and investment are needed to improve outcomes for people living with dementia, their families and carers,” she said.
The organisation is calling for better access to diagnosis, improved support for carers, more affordable respite services and greater investment in brain health.
For families affected by Alzheimer’s, the development of treatments that could preserve memory and independence for longer remains an especially important goal.
Xanamem is not a cure, and there is still considerable research ahead before doctors can determine whether it will become an effective treatment.
But the latest findings offer another encouraging step forward.
And for the hundreds of thousands of Australians living with dementia, and the families who love and care for them, every step towards better treatment is one worth celebrating.











